title: Transdermal estradiol plus oral medroxyprogesterone acetate replacement therapy in primary amenorrheic adolescents. Clinical, hormonal and metabolic aspects.
abstract: Twelve primary amenorrheic adolescents were treated with transdermal estradiol 100 micrograms (Estraderm TTS-100 (R)) twice weekly for 3 weeks, plus MPA 10 mg per os daily (Provera) for the last 11 days, following an interval of 1 week. A basic examination and a re-examination at 6- and 12-month intervals were carried out for clinical evaluation, hormonal assays, lipid, carbohydrate and bone metabolism. No significant changes were recorded on the FSH, LH, 17 beta-estradiol and PRL serum levels. A significant decrease of TC values and atheromatic indices 1 (TC/HDL) and 2 (LDL/HDL) was seen (P < 0.05) at the end of treatment. On the other hand a significant increase in apolipoproteins A1 was found. A beneficial effect was also recorded on the bone mass. Finally, no significant side-effects were reported. It is concluded that this kind of hormone replacement therapy is efficient and safe for the treatment of amenorrheic adolescents due to gonadal dysgenesis.
authors.affiliation: 1st Department of Obstetrics and Gynecology, University of Athens, Alexandra Hospital, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Creatsas
authors.forename: N
authors.initials: N
authors.lastname: Arefetz
authors.forename: P N
authors.initials: PN
authors.lastname: Adamopoulos
authors.forename: E
authors.initials: E
authors.lastname: Konstantellou
authors.forename: D
authors.initials: D
authors.lastname: Aravantinos
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000293:Adolescent; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D015519:Bone Density; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D015914:Estrogen Replacement Therapy; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005951:Glucose Tolerance Test; D006059:Gonadal Dysgenesis / Q000150:complications; D006801:Humans; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D011388:Prolactin / Q000097:blood
chemical_list: D008055:Lipids; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate